Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients. However, acquired resistance to EGFR-TKIs is widely detected across the world, and the exact mechanisms have not been fully demonstrate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jinrong Liao, Jinghui Lin, Dong Lin, Changyan Zou, Jessica Kurata, Renjang Lin, Zhiyong He, Ying Su
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/39b3f3767ebb4addbaa2847a1b555b5c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39b3f3767ebb4addbaa2847a1b555b5c
record_format	dspace
spelling	oai:doaj.org-article:39b3f3767ebb4addbaa2847a1b555b5c2021-12-02T16:08:00ZDown-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression10.1038/s41598-017-00901-62045-2322https://doaj.org/article/39b3f3767ebb4addbaa2847a1b555b5c2017-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00901-6https://doaj.org/toc/2045-2322Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients. However, acquired resistance to EGFR-TKIs is widely detected across the world, and the exact mechanisms have not been fully demonstrated until now. This study aimed to examine the role of miR-214 in the acquired resistance to erlotinib in NSCLC, and elucidate the underlying mechanisms. qRT-PCR assay detected higher miR-214 expression in the plasma of NSCLC patients with acquired EGFR-TKI resistance than prior to EGFR-TKI therapy, and in the generated erlotinib-resistant HCC827 (HCC827/ER) cells than in HCC827 cells. Bioinformatics analysis and dual-luciferase reporter assay indentified LHX6 as a direct target gene of miR-214, and LHX6 expression was detected to be down-regulated in erlotinib-resistant HCC827 cells. Transwell invasion assay revealed that overexpressing LHX6 reversed the increase in the invasive ability of HCC827 cells induced by miR-214 overexpression, and the CRISPR-Cas9 system-mediated LHX6 knockdown reversed the reduction in the invasion of erlotinib-resistant HCC827 cells caused by miR-214 down-regulation. The results of the present study demonstrate that down-regulation of miR-214 may reverse acquired resistance to erlotinib in NSCLC through mediating its direct target gene LHX6 expression.Jinrong LiaoJinghui LinDong LinChangyan ZouJessica KurataRenjang LinZhiyong HeYing SuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jinrong Liao Jinghui Lin Dong Lin Changyan Zou Jessica Kurata Renjang Lin Zhiyong He Ying Su Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
description	Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients. However, acquired resistance to EGFR-TKIs is widely detected across the world, and the exact mechanisms have not been fully demonstrated until now. This study aimed to examine the role of miR-214 in the acquired resistance to erlotinib in NSCLC, and elucidate the underlying mechanisms. qRT-PCR assay detected higher miR-214 expression in the plasma of NSCLC patients with acquired EGFR-TKI resistance than prior to EGFR-TKI therapy, and in the generated erlotinib-resistant HCC827 (HCC827/ER) cells than in HCC827 cells. Bioinformatics analysis and dual-luciferase reporter assay indentified LHX6 as a direct target gene of miR-214, and LHX6 expression was detected to be down-regulated in erlotinib-resistant HCC827 cells. Transwell invasion assay revealed that overexpressing LHX6 reversed the increase in the invasive ability of HCC827 cells induced by miR-214 overexpression, and the CRISPR-Cas9 system-mediated LHX6 knockdown reversed the reduction in the invasion of erlotinib-resistant HCC827 cells caused by miR-214 down-regulation. The results of the present study demonstrate that down-regulation of miR-214 may reverse acquired resistance to erlotinib in NSCLC through mediating its direct target gene LHX6 expression.
format	article
author	Jinrong Liao Jinghui Lin Dong Lin Changyan Zou Jessica Kurata Renjang Lin Zhiyong He Ying Su
author_facet	Jinrong Liao Jinghui Lin Dong Lin Changyan Zou Jessica Kurata Renjang Lin Zhiyong He Ying Su
author_sort	Jinrong Liao
title	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
title_short	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
title_full	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
title_fullStr	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
title_full_unstemmed	Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
title_sort	down-regulation of mir-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating lhx6 expression
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/39b3f3767ebb4addbaa2847a1b555b5c
work_keys_str_mv	AT jinrongliao downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT jinghuilin downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT donglin downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT changyanzou downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT jessicakurata downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT renjanglin downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT zhiyonghe downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression AT yingsu downregulationofmir214reverseserlotinibresistanceinnonsmallcelllungcancerthroughupregulatinglhx6expression
_version_	1718384648199864320

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Ejemplares similares